SOTIO Unveils Promising Preclinical Data for ADC Candidates SOT109 and SOT106, Signaling Best-in-Class Potential for Solid Tumor Therapies SOTIO Biotech, a clinical-stage biotechnology company and part of the PPF Group, has presented compelling preclinical data for two of its leading…
USPTO Invalidates Pharmacyclics Patent Challenged by BeiGene in BRUKINSA Dispute In a significant development in the ongoing intellectual property battle between two major players in the oncology therapeutics market, BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global biotechnology…
Titan Medical Group Launches Titan Workforce Solutions to Revolutionize Healthcare Staffing Nationwide Titan Medical Group, a leading name in the healthcare staffing industry, is proud to announce the official launch of Titan Workforce Solutions, a cutting-edge Managed Service Provider (MSP)…
AtriCure Reports Strong First Quarter 2025 Financial Results Driven by Product Innovation and Market Expansion AtriCure, Inc. (Nasdaq: ATRC), a global leader in developing innovative surgical solutions for the treatment of atrial fibrillation (Afib), left atrial appendage (LAA) management, and…
Xencor Reports Positive Interim Data From First-in-Human Study of XmAb942, Plans Phase 2b Trial for Inflammatory Bowel Disease Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company specializing in the development of engineered monoclonal antibodies and cytokines to treat cancer and…
QIAGEN Expands Digital PCR Portfolio With Advanced Lentivirus Solutions to Elevate Quality Control in Cell and Gene Therapy Manufacturing QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA), a global leader in sample and assay technologies for molecular diagnostics and life sciences,…
Sage Therapeutics Reports First Quarter 2025 Financial Results, Showcases Strong Momentum for ZURZUVAE and Pipeline Advancements Sage Therapeutics, Inc. (Nasdaq: SAGE) has announced its financial results for the first quarter ended March 31, 2025, highlighting solid progress in the commercialization…
DEFINE-HT Clinical Trial Shows Prospera™ Heart Accurately Predicts Outcomes and Outperforms Biopsy in Heart Transplant Surveillance Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, has announced the results of its landmark DEFINE-HT clinical trial,…
Mirion Reports Strong First Quarter 2025 Results and Updates Full-Year Guidance Amid Robust Market Demand Mirion Technologies, Inc. (“Mirion” or the “Company”) (NYSE: MIR), a leading provider of radiation detection, measurement, analysis, and monitoring technologies serving nuclear, medical, defense, and…
Guardant Health Unveils Compelling Data on Shield Multi-Cancer Detection Test at AACR 2025, Showcasing High Specificity and Sensitivity Across Ten Tumor Types Guardant Health, Inc. (Nasdaq: GH), a prominent leader in precision oncology, has released new clinical data demonstrating the…
Microba Life Sciences Achieves Breakthrough in IBD Diagnostics and Forms Strategic Partnership with Leading Gastroenterology Provider Microba Life Sciences Limited (ASX: MAP), a precision microbiome company at the forefront of next-generation diagnostics, today announced two major milestones that reinforce its…
D3 Bio Showcases Next-Generation KRAS G12C Inhibitor D3S-001 in Nature Medicine and AACR 2025 Presentation, Demonstrating Breakthrough Efficacy and Resistance Overcoming Potential D3 Bio, a clinical-stage biotechnology company at the forefront of precision oncology innovation, has announced a major milestone…